Advances in strategies to characterise tumours in the last decade have uncovered distinct molecular subtypes with prognostic and predictive relevance in both solid tumours and haematological malignancies. While conventional chemotherapy remains the mainstay in cancer therapeutics, the recognition of distinct “actionable genotypes” has led to a new paradigm shift towards targeted therapy, both as primary or adjunct treatment with chemotherapy, to improve patient outcomes.
This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.
